THUNDERCOMM
15.3.2023 04:57:35 CET | Business Wire | Press release
Thundercomm, a world leading IoT product and solution provider, announces the release of new offerings in its smart IoT module portfolio to lower the barriers to enter the market and accelerate innovation in various AIoT industry segments, including robotics, handheld devices, tablets and smart cameras.
TurboX C2210 SOM is powered by the Qualcomm® QRB2210 System-on-Chip (SoC). It's designed with an optimized Linux operating system, discrete memory for more memory options to save the cost, and system fast boot, supports 1080P@30FPS video decode and a long life cycle to 2028, aiming to bring advanced features to entry-level devices with better performance and improved power consumption. The TurboX C2210 SOM supports the Linux system and can be applied to a variety of products like entry-tier robotics, e-scooter, smart home dock, smart camera and rugged handheld, etc.
TurboX C4210 SOM is powered by the Qualcomm® QRB4210 SoC. It features triple ISPs for advanced dual-camera experience, dedicated Compute DSP for computer vision and video post-processing. It's designed to support advanced graphics, bringing high value features to mid-tier devices. It's an ideal platform for both industrial and consumer applications requiring high data rates multimedia function, and can be applied to a broad range of devices including robotics, dash camera, video conference, smart retail, etc.
TurboX C5430 SOM integrates the Qualcomm® QCS5430 SoC, a 6nm processor with superior performance, power efficiency, premium connectivity, and 3.5 TOPS computing power. It supports 4K@30FPS video decode and 4K@30FPS video encode, Wi-Fi 6E, long range bluetooth, four MIPI CSIs, as well as a rich set of peripheral interfaces. The C5430 SOM is a high performance AIoT SOM for building handheld devices, industrial robots, service robots, Edge Box, providing customers with hardware interfaces and software SDK to validate functions and build the prototype quickly.
“Robotics industry is growing faster than ever as technology continuously advances in 5G, computing power and AI. Today, we see robots in almost every aspect of our lives, helping us do much more than we can do alone. Our newly released C2210 SOM and C4210 SOM will unlock the potential of more innovations in robotics, lowering the barriers for brands to enter and compete efficiently in this growing market,” said Pier Zhang, Director of Product Marketing at Thundercomm. “We are offering not only the hardware SOM and dev kits, but also the robot brain, software solutions to help customers build future-proof robot products faster and cost-effectively.”
“We congratulate Thundercomm on the launch of their industry leading SOMs. Recognizing the innovation of these new products, Qualcomm Technologies recently announced Qualcomm® Robotics RB1 and RB2 Development Kits are based on TurboX C2210 and C4210 respectively,” said Dev Singh, vice president, business development, and head of building, enterprise and industrial automation, Qualcomm Technologies, Inc. “Boosting a suite of complete robotics capabilities, including pre-integrated sensors from TDK, cameras, and AI SDKs, our development kits will enable developers to more easily prototype everyday robotics applications thus helping push the IoT ecosystem forward.”
The Qualcomm Robotics RB1 and RB2 Development Kit and SOMs of TurboX C2210, C4210, C5430 are available now for evaluation and testing.
About Thundercomm
Thundercomm, a joint venture between Thunder Software Technology Co., Ltd and Qualcomm (China) Holding Co. Ltd., a subsidiary of Qualcomm Technologies, Inc., was established to accelerate innovation in the Internet of Things and automotive industry, providing one-stop solutions powered by Qualcomm Technologies. Through its capabilities in operating systems including Android, Linux, and others, abroad software and on-device AI technology portfolio, and a global sales and support network, Thundercomm is a valuable and trusted partner to global customers aiming to build high-quality, next-generation products and shorten time-to-commercialization. Learn more at www.thundercomm.com
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314006083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
